TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1893683

Group type: EXPERIMENTAL
Intervention: Active treatment (Vacusac)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active treatment (Vacusac) after placebo
Number of subjects: 22
Study: 6829673

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty treating 180 degrees of trabecular meshwork
Number of subjects: 40

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty treating 360 degrees of trabecular meshwork
Number of subjects: 40
Study: 31815678

Group type: EXPERIMENTAL
Intervention: Active hypertension management messages
Number of subjects: 373

Group type: COMPARATOR
Intervention: Passive health behavior messages
Number of subjects: 373
Study: 29864132

Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 615

Group type: COMPARATOR
Intervention: Kato-Katz methods
Number of subjects: 615
Study: 26597731

Group type: EXPERIMENTAL
Intervention: Performance goals group (n=23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Learning goals group (n=25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 24599532

Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide typhoid vaccine (25 μg, single dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 120
Study: 21917503

Group type: EXPERIMENTAL
Intervention: Saline rinsing of one eye after wearing PureVision™ lenses pre-soaked in ReNu MultiPlus® solution for 1 hour
Number of subjects: 13

Group type: COMPARATOR
Intervention: No rinsing (control)
Number of subjects: 13
Study: 20107304

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 0
Study: 17664472

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 92

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 92
Study: 16085692

Group type: EXPERIMENTAL
Intervention: PS‐341 1.5 mg/m(2) i.v. bolus on days 1, 4, 8 and 11 (Arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PS‐341 1.0 mg/m(2) plus gemcitabine 1,000 mg/m(2) i.v. on days 1 and 8 (Arm B)
Number of subjects: 81
Study: 12489601

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study: 9833567

Group type: EXPERIMENTAL
Intervention: Crime committed in an unusual manner
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Prosecution motive information (strong, reasonable motive)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Defense motive information (crazy, unreasonable motive)
Number of subjects: 371
Study: 7865648

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2518858

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1065757

Group type: EXPERIMENTAL
Intervention: Supervised daily toothbrushing and flossing (10 sessions of instruction in plaque removal)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control group (no instruction in oral hygiene procedures)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Supervised daily toothbrushing and flossing
Number of subjects: 481
Study: 31093987

Group type: EXPERIMENTAL
Intervention: Counseling based on the choice theory
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 50
Study: 31738351

Group type: EXPERIMENTAL
Intervention: Yogurt group (consumed 112 mL yogurt drink fermented with OLL1073R‐1 daily for 16 weeks)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Control group (no yogurt consumption during the trial)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Yogurt group
Number of subjects: 961

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 961
Study: 28565995

Group type: EXPERIMENTAL
Intervention: Free, healthy school meal served every school day for 6 months
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no free school meal)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Free, healthy school meal
Number of subjects: 164
Study: 25841077

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study: 23810041

Group type: EXPERIMENTAL
Intervention: Upper Hawley/lower bonded
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Upper Essix/lower bonded
Number of subjects: 90

Group type: COMPARATOR
Intervention: Extraction treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonextraction treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low discrepancy index scores group
Number of subjects: 90

Group type: COMPARATOR
Intervention: High discrepancy index scores group
Number of subjects: 90
Study: 21342748

Group type: EXPERIMENTAL
Intervention: Feed supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organic chromium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suffolk×Dorper (SD) genotype
Number of subjects: 0
Study: 19763999

Group type: EXPERIMENTAL
Intervention: Glucose plus fructose + endurance exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucose plus fructose + strength exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose + endurance exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose + strength exercise
Number of subjects: 20
Study: 17173225

Group type: EXPERIMENTAL
Intervention: Ribavirin (2 g 3 times daily for 10 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Supportive care (control group)
Number of subjects: 14
Study: 15028553

Group type: EXPERIMENTAL
Intervention: S.S.GRIN (Social Skills GRoup INtervention)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No-treatment control (C)
Number of subjects: 381
Study: 27841153

Group type: EXPERIMENTAL
Intervention: Test formulation of morniflumate 350-mg tablets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation of morniflumate 350-mg tablets
Number of subjects: 38
Study: 9277640

Group type: EXPERIMENTAL
Intervention: Standard 600‐kcal breakfast at 8 AM (phase A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prolonged fasting (phase B)
Number of subjects: 20
Study: 8436090

Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO) 25 ml daily for 8 weeks
Number of subjects: 34
Study: 3946922

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical betaxolol 1%
Number of subjects: 24
Study: 30954948

Group type: EXPERIMENTAL
Intervention: Online injury prevention programme; participants received access to information on evidence-based risk factors and advice to reduce injury risk.
Number of subjects: 2378

Group type: COMPARATOR
Intervention: Control group; participants followed their regular preparation for the running event.
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Online injury prevention programme; specifically for runners with no injuries in the 12 months preceding the trial.
Number of subjects: 2378
Study: 29649927

Group type: EXPERIMENTAL
Intervention: Spaced practice with different environmental context scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spaced practice with the same environmental context scene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massed practice with different environmental context scenes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massed practice with the same environmental context scene
Number of subjects: 0
Study: 26739253

Group type: EXPERIMENTAL
Intervention: Holistic lifestyle intervention (CHIP Germany), 40-hour coaching program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 23588342

Group type: EXPERIMENTAL
Intervention: 4-hour outpatient methotrexate infusion
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 24-hour inpatient methotrexate infusion
Number of subjects: 161

Group type: COMPARATOR
Intervention: Healthy control populations
Number of subjects: 161
Study: 22172966

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo treatment for 3 weeks
Number of subjects: 71
Study: 20815898

Group type: EXPERIMENTAL
Intervention: Active nCPAP
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham nCPAP
Number of subjects: 35
Study: 17140611

Group type: EXPERIMENTAL
Intervention: Phonological awareness and grapheme-to-phoneme conversion training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-auditory training (Control)
Number of subjects: 10
Study: 15761456

Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical compression with the Compressar
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical compression with the Femostop
Number of subjects: 90
Study: 14702863

Group type: EXPERIMENTAL
Intervention: Health education intervention provided by nurses
Number of subjects: 0
Study: 10195630

Group type: EXPERIMENTAL
Intervention: Autoclaved vaccine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nonautoclaved vaccine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 8892450

Group type: EXPERIMENTAL
Intervention: Cisplatin (total dose 100-185 mg/m²)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Radiotherapy (dose ranged from 59.5 to 76.5 Gy)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Age groups (under 30, 30-50, over 50)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Postirradiation serous otitis media (SOM)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cisplatin and radiation dose or fractionation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 132
Study: 1734985

Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment and home blood glucose monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 0
Study: 6465581

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg) with sodium citrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Meperidine alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meperidine plus metoclopramide (20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam plus metoclopramide (20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (meperidine or diazepam without metoclopramide)
Number of subjects: 60
Study: 2429084

Group type: COMPARATOR
Intervention: Atenolol (50 mg once daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: ICI 118,551 (20 mg t.i.d.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29656373

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAPID3 remission/LDA
Number of subjects: 0
Study: 28185792

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cisplatin (Doc-Cis)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Pemetrexed plus Cisplatin (Pem-Cis)
Number of subjects: 148
Study: 25731897

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (40 mg/kg) and nebulized epinephrine (0.1 ml/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nebulized epinephrine (0.1 ml/kg)
Number of subjects: 120
Study: 24085591

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 21422467

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 100
Study: 18326596

Group type: EXPERIMENTAL
Intervention: High rTFA diet (10.2 g/2500 kcal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: iTFA diet (10.2 g/2500 kcal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Moderate rTFA diet (4.2 g/2500 kcal)
Number of subjects: 38
Study: 16436342

Group type: EXPERIMENTAL
Intervention: Nadifloxacin 1% cream
Number of subjects: 474

Group type: COMPARATOR
Intervention: Erythromycin 2% cream
Number of subjects: 474
Study: 14628252

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (1, 3, and 10 ng/kg/min for 45 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: AT (1)-receptor antagonist (160 mg valsartan) prior to angiotensin II infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion and AT (1)-antagonist administration
Number of subjects: 9
Study: 10737282

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Atenolol (by race)
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Prazosin (by race)
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Diltiazem (by race)
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Captopril (by race-region)
Number of subjects: 1105
Study: 8731547

Group type: EXPERIMENTAL
Intervention: Inpatient treatment for PTSD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment/wait list comparison group (weekly PTSD outpatient group therapy)
Number of subjects: 24
Study: 1576620

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Clindamycin+aminoglycoside (C+A)
Number of subjects: 352
Study: 3902602

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg orally once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31790425

Group type: EXPERIMENTAL
Intervention: Brief intervention for cannabis use
Number of subjects: 262
Study: 29744866

Group type: EXPERIMENTAL
Intervention: Dietary counseling and twice‐weekly exercise classes
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: High physical activity level (≥16 metabolic equivalent of task‐hours moderate‐to‐vigorous physical activity/week)
Number of subjects: 606
Study: 26474192

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX (Group 2)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (Group 3)
Number of subjects: 261

Group type: COMPARATOR
Intervention: placebo + MTX (Group 1)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: golimumab + MTX (Groups 2 and 3 combined)
Number of subjects: 261
Study: 24561570

Group type: EXPERIMENTAL
Intervention: Intra-lesion (IL) abciximab
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: TA with IL abciximab
Number of subjects: 452

Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 452

Group type: COMPARATOR
Intervention: No TA
Number of subjects: 452
Study: 22506607

Group type: EXPERIMENTAL
Intervention: 38-mm standard transducer
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25-mm hockey stick transducer
Number of subjects: 0
Study: 21223649

Group type: EXPERIMENTAL
Intervention: Pressure treatment group (custom pressure garment with 10% strain rate of pressure + 9 mm thick local pressure padding, worn more than 23 hours per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pressure treatment group (5.6 mm Hg pressure)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pressure treatment group (2.8 and 5.6 mm Hg pressure)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pressure treatment group (various pressure levels)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SPMS (smart pressure monitored suit)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 45
Study: 18722970

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Radical Hysterectomy (TLRH) / Total Robotic Radical Hysterectomy (TRRH)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Total Abdominal Radical Hysterectomy (TARH)
Number of subjects: 740
Study: 16052760

Group type: EXPERIMENTAL
Intervention: Tyrian Self Priming Etchant + One Step Plus (TY)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus Self‐Etch Primer + Optibond Solo Plus (SO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid (0.5 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etch-and-rinse adhesive systems
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single Bond (SB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ScotchBond Multi‐Purpose Plus (SC)
Number of subjects: 30
Study: 14662569

Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Triethanolamine polypeptide
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 92
Study: 10199756

Group type: EXPERIMENTAL
Intervention: GnRH analog plus human PTH-(1-34) (40 microg/day, s.c.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: GnRH analog alone (nafarelin acetate; 200 microg, intranasally, twice daily)
Number of subjects: 38
Study: 8849298

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (Funazol)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Topical itraconazole
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (Sporanox)
Number of subjects: 1
Study: 2236467

Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluphenazine plasma levels
Number of subjects: 39
Study: 484261

Group type: EXPERIMENTAL
Intervention: Treatment for 8 days
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment for 15 days
Number of subjects: 252
Study: 30759228

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Quadrivalent live‐attenuated influenza vaccine (LAIV)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 415
Study: 31741066

Group type: EXPERIMENTAL
Intervention: Bone-filling mesh container (BFMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 40
Study: 29884405

Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of up to 200,000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks
Number of subjects: 12
Study: 27385151

Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Contrast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Carbon dioxide
Number of subjects: 23
Study: 24921418

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented treatment modality
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Insight oriented treatment modality
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Internet therapy
Number of subjects: 391

Group type: COMPARATOR
Intervention: Orthodox Jews
Number of subjects: 391

Group type: COMPARATOR
Intervention: Non-Orthodox Jews
Number of subjects: 391
Study: 21628603

Group type: COMPARATOR
Intervention: Aclidinium IV doses (25-400 µg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhaled aclidinium (200 µg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18817967

Group type: EXPERIMENTAL
Intervention: Polyvinyl matrix
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Putty matrix
Number of subjects: 5

Group type: COMPARATOR
Intervention: Putty matrix pre-cooled at 4 degrees C
Number of subjects: 5

Group type: COMPARATOR
Intervention: Putty matrix pre-cooled in freezer
Number of subjects: 5
Study: 17452937

Group type: EXPERIMENTAL
Intervention: Automatic device for continuous regulation of tracheal tube cuff pressure (n = 73)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Routine care of the cuff pressure (control group, n = 69)
Number of subjects: 142
Study: 15370401

Group type: EXPERIMENTAL
Intervention: Topical phenytoin sodium suspension 2%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical phenytoin sodium suspension 4%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 45
Study: 11641743

Group type: EXPERIMENTAL
Intervention: Thermally stressed olive oil (TSOL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Thermally stressed safflower oil (TSAF)
Number of subjects: 14
Study: 9684780

Group type: EXPERIMENTAL
Intervention: YM 337
Number of subjects: 0

Group type: COMPARATOR
Intervention: ReoPro (Control)
Number of subjects: 0
Study: 7850531

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic parenteral nutrition (1.44 U/kg/day regular human insulin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 11
Study: 3060308

Group type: EXPERIMENTAL
Intervention: Toothpastes containing sodium monofluorophosphate (SMFP) at fluoride levels of 1000, 1500, and 2500 ppm F
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Toothpastes incorporating zinc citrate
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Zinc-free pastes
Number of subjects: 3000
Study: 31514201

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29294501

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg
Number of subjects: 708
Study: 25897707

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lecture-based education
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 20
Study: 24708775

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 10